TXG Overview

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Wall Street analysts forecast TXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10X Genomics Inc revenue for the last quarter amounts to 154.88M USD, increased 9.84

10X Genomics Inc. EPS for the last quarter amounts to -0.28 USD, decreased -44.00

10X Genomics Inc (TXG) has 1306 emplpoyees as of March 11 2026.

Today TXG has the market capitalization of 2.38B USD.